(GuruFocus, November 3, 2009) Investment Guru Edward Owens reported his trading activities and quarter end holdings. We reviewed his top holdings in an earlier article. Here are the top purchases for the quarter:
Conclusion
Overall, in the heated debate of health care reform, Edward Owens did not have a very active trading season.
GuruFocus provides real time information and insights of Investment Gurus such as Warren Buffett and Edward Owens for Premium Members. If you are not a premium member, click here to sign up or upgrade. 7-Day Free Trial is available.
No. 1: Cubist Pharmaceuticals Inc. (CBST, Financial), Buy: 0.04% of the portfolio to Total: 383,528 Shares
Cubist Pharmaceuticals Inc. is a biopharmaceutical company focused on the research development and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. In the U.S. Cubist markets CUBICIN the first antibiotic in a new class of antiinfectives called lipopeptides. The Cubist product pipeline includes our lipopeptide program and our natural products screening program. Cubist is headquartered in Lexington MA. Cubist Pharmaceuticals Inc. has a market cap of $982 million; its shares were traded at around $17 with a P/E ratio of 10.5 and P/S ratio of 2.3.No. 2: Cephalon Inc. (CEPH, Financial), Add: 0.24% of the portfolio to Total: 2,752,000 Shares
Cephalon is an international biopharmaceutical company focused on thediscovery development and marketing of products to treat sleep disordersneurological disorders cancer and pain. In addition to an active research and development program they market products in the United States and various countries in Europe. Cephalon Inc. has a market cap of $4.05 billion; its shares were traded at around $54.24 with a P/E ratio of 9.3 and P/S ratio of 2. Cephalon Inc. had an annual average earning growth of 10.1% over the past 5 years.No. 3: Johnson & Johnson (JNJ, Financial), Add: 0.2% of the portfolio - Total: 1,400,000 Shares
Johnson & Johnson is engaged in the manufacture and sale of a broad range of products in the health care field in many countries of the world. The company's worldwide business is divided into three segments: Consumer; Pharmaceutical; and Professional. Johnson & Johnson has a market cap of $163.94 billion; its shares were traded at around $59.49 with a P/E ratio of 13.1 and P/S ratio of 2.6. The dividend yield of Johnson & Johnson stocks is 3.3%. Johnson & Johnson had an annual average earning growth of 12.5% over the past 10 years. GuruFocus rated Johnson & Johnson the business predictability rank of 4.5-star.No. 4: ONYX Pharmaceuticals Inc. (ONXX, Financial), Add: 0.03% of the portfolio - Total: 807,200 Shares
Onyx Pharmaceuticals Inc is developing innovative products for the treatment of cancer. Onyx Pharmaceuticals Inc. has a market cap of $1.62 billion; its shares were traded at around $26.45 with and P/S ratio of 8.3. Onyx Pharmaceuticals Inc. had an annual average earning growth of 1.3% over the past 5 years.Conclusion
Overall, in the heated debate of health care reform, Edward Owens did not have a very active trading season.
GuruFocus provides real time information and insights of Investment Gurus such as Warren Buffett and Edward Owens for Premium Members. If you are not a premium member, click here to sign up or upgrade. 7-Day Free Trial is available.
